RedHill Biopharma (NASDAQ: RDHL) CFO details ADS, RSU and option holdings

Rhea-AI Filing Summary

RedHill Biopharma Ltd. Chief Financial Officer Ingber Razi filed a Form 3 reporting existing equity interests in the company, rather than new open‑market trades. The filing lists American Depositary Shares (ADSs), restricted share units (RSUs) and stock options tied to Ordinary Shares.

The holdings include 27,756 unvested RSUs, each for one ADS, with each ADS representing 10,000 Ordinary Shares of par value NIS 0.01. The filing also notes 6,691 ADSs that are convertible at any time with no expiration date, plus fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares at fixed exercise prices per ADS, expiring between August 29, 2028 and April 28, 2031.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ingber Razi

(Last) (First) (Middle)

21 HA'ARBA'A STREET

(Street)

TEL AVIV 6473921

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
RedHill Biopharma Ltd. [ RDHL ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	277,560,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(2)	(2)	Ordinary Shares	66,910,000	(2)	D
Stock Option (Right to Buy)	(3)	(3)	Ordinary Shares	20,000	(3)	D
Stock Option (Right to Buy)	(4)	(4)	Ordinary Shares	30,000	(4)	D
Stock Option (Right to Buy)	(5)	(5)	Ordinary Shares	170,000	(5)	D
Stock Option (Right to Buy)	(6)	(6)	Ordinary Shares	230,000	(6)	D

Explanation of Responses:

1. Represents 27,756 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.

2. Represents 6,691 ADSs, which are convertible at any time, at the holder's election and have no expiration date.

3. Represents stock option to purchase 20,000 Ordinary Shares (equivalent to 2 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on August 29, 2028.

4. Represents stock option to purchase 30,000 Ordinary Shares (equivalent to 3 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.

5. Represents stock option to purchase 170,000 Ordinary Shares (equivalent to 17 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,720 per ADS and the option expires on June 30, 2030.

6. Represents stock option to purchase 230,000 Ordinary Shares (equivalent to 23 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.

	/s/ Razi Ingber	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does RedHill Biopharma (RDHL) CFO Ingber Razi report owning on this Form 3?

The CFO reports existing holdings of ADSs, unvested RSUs and stock options. These positions relate to Ordinary Shares of RedHill Biopharma Ltd. and reflect equity-based compensation and ownership, not new open-market purchases or sales.

How many restricted share units does the RDHL CFO report on Form 3?

Ingber Razi reports 27,756 unvested restricted share units, each tied to one American Depositary Share. Each ADS represents 10,000 Ordinary Shares of par value NIS 0.01, and the RSUs are subject to time-based vesting and settled in Ordinary Shares.

What American Depositary Shares are disclosed by the RDHL CFO in this filing?

The filing states that 6,691 American Depositary Shares are held, which are convertible at any time at the holder’s election and have no expiration date. These ADSs represent Ordinary Shares of RedHill Biopharma Ltd. under its depositary structure.

What stock options are reported by RedHill Biopharma (RDHL) CFO on Form 3?

The CFO reports fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares under the RedHill 2010 Option Plan. Each grant has a stated exercise price per ADS and specific expiration dates between 2028 and 2031.

When do the RDHL CFO’s reported stock options expire?

The stock options described in the filing expire on August 29, 2028, May 6, 2029, June 30, 2030 and April 28, 2031. Each option grant is fully vested and exercisable, with an exercise price specified per American Depositary Share.

Are the equity awards reported by the RDHL CFO already vested?

The filing explains that all listed stock options are fully vested and exercisable, but the 27,756 RSUs are unvested and subject to time-based vesting. Once vested, these RSUs are settled in Ordinary Shares corresponding to the linked American Depositary Shares.